Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale.


Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2020
Historique:
received: 23 02 2020
accepted: 25 03 2020
pubmed: 17 6 2020
medline: 19 8 2021
entrez: 17 6 2020
Statut: ppublish

Résumé

The Unified Dyskinesia Rating Scale (UDysRS) is a well-established tool for producing comprehensive assessments of severity and disability associated with dyskinesia in patients with Parkinson's disease (PD). The scale was originally developed in English, and a broad international effort has been undertaken to develop and validate versions in additional languages. Our aim was to validate the Hebrew version of the UDysRS. We translated the UDysRS into Hebrew, back-translated it into English, and carried out cognitive pretesting. We then administered the scale to non-demented native Hebrew-speaking patients who fulfilled the Brain Bank diagnostic criteria for probable PD (n = 250). Data were compared to the Reference Standard data used for validating UDysRS translations. The different portions of the Hebrew UDysRS showed high internal consistency (α ≥ 0.92). A confirmatory factor analysis in which we compared the Hebrew UDysRS to the Reference Standard version produced a comparative fit index (CFI) of 0.98, exceeding the threshold criterion of CFI > 0.9 indicating factor validity. A secondary exploratory factor analysis provided further support to the consistency between the factor structures of the Hebrew and Reference Standard versions of the UDysRS. The UDysRS Hebrew version shows strong clinimetric properties and fulfills the criteria for designation as an official International Parkinson and Movement Disorder Society-approved translation for use in clinical and research settings.

Sections du résumé

BACKGROUND
The Unified Dyskinesia Rating Scale (UDysRS) is a well-established tool for producing comprehensive assessments of severity and disability associated with dyskinesia in patients with Parkinson's disease (PD). The scale was originally developed in English, and a broad international effort has been undertaken to develop and validate versions in additional languages. Our aim was to validate the Hebrew version of the UDysRS.
METHODS
We translated the UDysRS into Hebrew, back-translated it into English, and carried out cognitive pretesting. We then administered the scale to non-demented native Hebrew-speaking patients who fulfilled the Brain Bank diagnostic criteria for probable PD (n = 250). Data were compared to the Reference Standard data used for validating UDysRS translations.
RESULTS
The different portions of the Hebrew UDysRS showed high internal consistency (α ≥ 0.92). A confirmatory factor analysis in which we compared the Hebrew UDysRS to the Reference Standard version produced a comparative fit index (CFI) of 0.98, exceeding the threshold criterion of CFI > 0.9 indicating factor validity. A secondary exploratory factor analysis provided further support to the consistency between the factor structures of the Hebrew and Reference Standard versions of the UDysRS.
CONCLUSION
The UDysRS Hebrew version shows strong clinimetric properties and fulfills the criteria for designation as an official International Parkinson and Movement Disorder Society-approved translation for use in clinical and research settings.

Identifiants

pubmed: 32541146
pii: 000507827
doi: 10.1159/000507827
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

356-362

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Achinoam Faust-Socher (A)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel, achinoams@tlvmc.gov.il.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, achinoams@tlvmc.gov.il.

Saar Anis (S)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.

Meir Kestenbaum (M)

Neurological Department, Meir Medical Center, Tel Aviv University, Tel-Aviv, Israel.

Herzl Shabtai (H)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.

Tali Taichman (T)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.

Aya Bar David (A)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.

Adi Ezra (A)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.

Chava Peretz (C)

Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Alina Rosenberg (A)

Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Marina Brozgol (M)

The Center for the Study of Movement, Cognition, and Mobility (CMCM), Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.

Talia Herman (T)

The Center for the Study of Movement, Cognition, and Mobility (CMCM), Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.

Glenn T Stebbins (GT)

Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA.

Christopher G Goetz (CG)

Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA.

Pablo Martínez-Martín (P)

Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.

Sheng T Luo (ST)

Department of population health sciences, Duke University School of Medicine, Durham, North Carolina, USA.

Xuehan Ren (X)

Gilead Sciences, Inc., Foster City, California, USA.

Nir Giladi (N)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.

Tanya Gurevich (T)

Movement Disorders Unit, Neurology Department, Neurological Institute, Tel Aviv Medical Center, Tel-Aviv, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH